Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials - Wikidata - awgldk - TriplyDB

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

http://www.wikidata.org/entity/Q28394899

about

HIV-1 prophylactic vaccines: state of the art UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.New approaches to design HIV-1 T-cell vaccines HIV vaccines: lessons learned and the way forward.Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques.Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses Induction of an Antibody Response against Plasmodium falciparum F2RIIEBA by Heterologous Prime-boost Immunisation.Short Communication: Parallel Analyses of Systemic and Local Vaccinations with Envelope Formulated in Adjuvant for Induction of HIV-Specific Antibodies in the Vaginal Mucosa.Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.Virus-Like-Vaccines against HIV.Respiratory syncytial virus vaccine development

P2860

Q26740042-671EFA13-5DF4-4189-BEE9-AA52F6470470 Q30414377-E0C2E10C-7432-475E-92C3-20C4BC3AAB32 Q34274849-A434BE60-B27C-4D80-A376-9B475455425B Q34342558-D972F759-B81C-4A74-8860-A4C5FED10BCB Q34437167-207F7E6E-FAC5-46E9-A625-B703496BFECE Q34485178-604DF1F7-4D4E-48E5-B659-1A4940C7C787 Q34511092-81896F73-F940-45BE-8039-6EE25896E604 Q35053133-70F7702E-45AD-40D2-BA82-42C755B53A69 Q35821368-23A5AF8D-CF26-4BDE-999D-1B9FCBEEEFAE Q36475897-B04AAE39-D541-4793-AFFE-653D147E6A1C Q37118707-BAE81DAC-32BA-4C54-B04A-993B7FB790E6 Q37236697-72A3C26C-F1F9-452B-AA49-EDE62D303F66 Q40459706-B174A65C-A72D-413C-8A7C-F2DD8E1EE2E1 Q41931861-AD2E7357-A459-4D6B-9B0A-523562D4DF98 Q47218587-6C9AD306-75BF-4376-9F5C-C8B7AB607C29 Q50034030-F3F53F3D-9386-499E-A3D2-DB785F17060A Q56893551-7412921E-F02B-412A-A1FA-69D717ECEB87

P2860

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

http://www.wikidata.org/entity/Q28394899

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@ast

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@en

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@nl

type

label

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@ast

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@en

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@nl

prefLabel

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@ast

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@en

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@nl

P1433

Q28394899-1551F9B9-BBAB-4EFF-B4A5-6FEB36E844EB

P1476

Q28394899-220FB95B-7698-4E99-8306-B8C6E4B03212

P2093

Q28394899-0642F24A-590D-4425-A8FF-F54F84F7BCBF

Q28394899-19DD910A-A627-4C17-AB43-AF63A1825E61

Q28394899-39438F0E-A6A5-4BCD-8AA7-E07893BFC8AB

Q28394899-40E97A9F-0529-463F-9CF0-BE3E948B817B

Q28394899-5915AE4C-C6F3-48AA-A207-8CB8D7B25644

Q28394899-9B97852F-D26F-40C9-B7EF-1C487DAB7563

Q28394899-BC623F6F-D6C4-4EEC-8FC7-CE556481C2CA

Q28394899-D58A505B-312B-4FDF-BB54-A36F467BAEFB

Q28394899-E020A90C-C48F-44FE-9CB0-DD4C098CFED4

Q28394899-E87FE123-D1DC-4B7C-A6DD-E2D4FDECC9F3

P2860

Q28394899-00CC309F-BBC4-44CB-82C6-71243CD4E3F9

Q28394899-029801A5-1B30-4306-90A6-8D913380828A

Q28394899-03E65425-C2EA-479A-ABA8-D3673AF0E8B4

Q28394899-04DFE1BC-E6F2-42D8-B763-E6ADD70AA5CC

Q28394899-06B3FB0D-AD66-481D-8CCD-F1F420A27D00

Q28394899-06DC5189-5616-400F-BFDD-7093EFA47219

Q28394899-08675569-9698-481E-9B90-7DCD7C96A8A4

Q28394899-09A51FDA-D0C8-4778-BA9A-4F34E2BC5C9C

Q28394899-0A5BCF96-CFA7-4C78-BA05-BB94D567BFF8

Q28394899-0BED7CC8-E097-420E-B594-A96FE2592264

P304

Q28394899-F6C2A9BC-63E4-4052-A46E-7F85416FAFAF

P31

Q28394899-2309D447-4E97-41C1-A182-802304A6464E

P356

Q28394899-5726FFF4-9A87-442D-B420-A04BCC6D28E4

P407

Q28394899-61ADC22D-D666-46C1-BDC3-8326F767992B

P433

Q28394899-18F7F34E-26D0-41DF-B2AE-DE7014C74302

P478

Q28394899-415A4170-C8C0-413E-8970-81592B0D7AE6

P577

Q28394899-62F88C62-4F1B-47D6-9B73-5ACFA02F08C4

P5875

Q28394899-F17EF0B5-8D03-4B6E-9AAC-323A0CDB1B50

P698

Q28394899-E29E5123-BE1B-4500-B2AE-6495AE03DB1B

P932

Q28394899-1498E8FB-7915-40FB-9011-913D9F0DCD42

P356

P1433

P1476

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

@en

P2093

Bart G Jones

http://www.w3.org/2001/XMLSchema#string

Julia L Hurwitz

http://www.w3.org/2001/XMLSchema#string

Karen S Slobod

http://www.w3.org/2001/XMLSchema#string

Kristen Branum

http://www.w3.org/2001/XMLSchema#string

Nanna Howlett

http://www.w3.org/2001/XMLSchema#string

Pamela Freiden

http://www.w3.org/2001/XMLSchema#string

Patricia Flynn

http://www.w3.org/2001/XMLSchema#string

Robert Sealy

http://www.w3.org/2001/XMLSchema#string

Scott A Brown

http://www.w3.org/2001/XMLSchema#string

Sherri L Surman

http://www.w3.org/2001/XMLSchema#string

P2860

Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Timing the ancestor of the HIV-1 pandemic strains

Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene

Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine

Defective antigen processing in GILT-free mice

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

The isolation of structural genes from libraries of eucaryotic DNA

Ecological and immunological determinants of influenza evolution.

P304

435-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/V2020435

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43227479

http://www.w3.org/2001/XMLSchema#string

P698

20407589

http://www.w3.org/2001/XMLSchema#string

P932

2855973

http://www.w3.org/2001/XMLSchema#string